Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.69 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639126 | 0.98 | P2RX3 (0.69) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3668653 | 0.96 | P2RX3 (0.71) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3643653 | 0.95 | P2RX3 (0.70) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3639532 | 0.82 | P2RX3 (1.00) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3638517 | 0.80 | P2RX3 (0.54) | P2RX3KDM4EALDH1A1GAAGLA | |
| SCHEMBL3636444 | 0.79 | P2RX3 (0.75) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL4223784 | 0.79 | P2RX3 (0.72) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3639128 | 0.79 | P2RX3 (0.69) | P2RX3TACR2KDM4EALDH1A1GAA | |
| SCHEMBL3640214 | 0.78 | TACR2 (0.67) | P2RX3TACR2KDM4EALDH1A1 | |
| SCHEMBL3638519 | 0.78 | P2RX3 (0.67) | P2RX3TACR2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | P2RX3 53/4885TACR2 158/4885KDM4E 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.